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Abstract
Background: In order to provide some basis for effective dosage regimens that optimize efficacy with respect to
bacteriological and clinical cures, the in vivo activity of cefquinome against a clinical Escherichia coli (E.coli) strain
(the minimum inhibitory concentration value for this strain equals to the MIC90 value of 0.25 μg/ml for 210 E.coli
strains isolated from pigs) was investigated by using a piglet tissue-cage infection model. The aim was to elucidate
the pharmacokinetic/pharmacodynamics (PK/PD) index associated with cefquinome efficacy, and then to identify
the magnitude of the PK/PD parameter required for different degree of efficacy in clinical treatment.
Results: Tissue-cage infection model was established in piglets, and then the animals received intramuscular
injection of cefquinome twice a day for 3 days to create a range of different drug exposures. The tissue-cage fluid
was collected at 1, 3, 6, 9 and 12 h after every drug administration for drug concentration determination and
bacteria counting. Different cefquinome regimens produced different percentages of time during that drug
concentrations exceeded the MIC (%T >MIC), ranging from 0 % to 100 %. Cefquinome administration at 0.2, 0.4, 0.6,
0.8, 1, 2 and 4 mg/kg reduced the bacterial count (log10 CFU/mL) in tissue-cage fluid by −1.00 ± 0.32, −1.83 ± 0.08,
−2.33 ± 0.04, −2.96 ± 0.16, −2.99 ± 0.16, −2.93 ± 0.11, −3.43 ± 0.18, respectively. The correlation coefficient of the PK/
PD index with antibacterial effect of the drug was 0.90 for %T > MIC, 0.62 for AUC0–12/MIC, and 0.61 for Cmax/MIC,
suggesting the most important PK/PD parameter was %T > MIC. A inhibitory form of sigmoid maximum effect
(Emax) model was used to estimate %T > MIC, and the respective values required for continuous 1/6-log drop, 1/3-
log drop and 1/2-log drop of the clinical E.coli count during each 12 h treatment period were 3.97 %, 17.08 % and
52.68 %.
Conclusions: The data derived from this study showed that cefquinome exhibited time-dependent killing profile.
And from the results of the present study, it can be assumed that when %T >MIC reached 52.68 %, cefquinome
could be expected to be effective against a clinical E.coli strain for which the MIC value is below 0.128 μg/ml
(3-log drop of bacteria count can be achieved after six successive administrations for 3 days).
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Background
Overuse and misuse of antimicrobial drugs have favoured
the growth of resistant organisms. Resistance can spread
to other microbial populations (including those bacteria
not previously exposed to antimicrobial agents), jeopardiz-
ing humans and animals. Among the documented misuses
contributing to drug resistance are inappropriate dosage
regimens (dose, dosage interval, duration of treatment,
route and conditions of administration) (Anonymous
1998). Rational antibiotic therapy requires dosage regi-
mens to be optimized, not only to guarantee clinical effi-
cacy, but also to minimize the selection and spread of
resistant pathogens [1].
Jacobs thought pharmacokinetics (PK) and pharmaco-
dynamics (PD) should be considered to establish optimal
dosing regimens for antimicrobials [2]. Besides, Toutain
and Lees thought that the parameters derived from PK/
PD modelling may be used as an alternative and pre-
ferred approach to dose titration studies for selecting ra-
tional dosage regimens (both dose and dosing interval)
for further evaluation in clinical trials [3].
Since 1935 when Domagk demonstrated that prontosil
provided effective therapy in a murine pneumococcal
infection model, the use of animal infection models has
become an integral part of the evaluation of new anti-
microbial agents and new therapeutic approaches for
clinical trials in humans. Compared with in vitro studies,
animal models provide a dynamic interaction of multiple
factors relating to the host, drug and pathogens [4].
Tissue cages were first used by Guyton [5] to study
interstitial fluid physiology and composition. In the
veterinary field, the tissue-cage model has been used to
study the PK/PD integration of antimicrobial drugs in
several species, such as sheep [6], goats [7], pigs [8, 9]
and calves [10, 11].
Cefquinome is a fourth generation broad-spectrum
cephalosporin developed solely for veterinary use and
approved for the treatment of respiratory tract disease,
acute mastitis and foot rot in cattle, calf septicemia,
metritis-mastitis-agalactia syndrome in sows and re-
spiratory diseases in pigs [12, 13]. It also has been used
to prevent severe pneumonia in piglets (caused by path-
ogens such as Actinobacillus pleuropneumonia, Klebsi-
ella pneumonia, and Streptococcus pneumonia) and to
establish pig herds free of pneumonia by combining its
use with strategic vaccination [14].
Although PK and ex vivo PD of cefquinome against
Escherichia coli (E.coli) 25922 has been explored pre-
viously [9], there is no report so far concerning the
in vivo PK/PD analysis of cefquinome in piglets. Pre-
vious studies about in vivo PK/PD of the antibacterial
agent were mostly against various standard strains,
hardly any against the clinical bacterial strains. There-
fore, in the present study, we collected 210 E.coli clinical
strains isolated from pigs with common colibacillosis,
and one strain whose minimum inhibitory concentration
(MIC) equals to the MIC90 of 210 strains was used for
tissue-cage infection model. After the tissue-cage infec-
tion model was established, the animals were treated
with multiple dosing, which was consistent with the
actual situation of clinical treatment. The aim of this
study was to characterize the PK/PD parameter that is
predictive of the efficacy of cefquinome against the
clinical E.coli strain in a piglet tissue-cage infection
model for the first time. Furthermore, magnitude of the
PK/PD parameter will also be determined for bacteri-
cidal efficacy in clinical treatment. It is proposed that
these findings can provide a rational approach to design-
ing dosage schedules that optimize efficacy with respect
to bacteriological and clinical cures.
Methods
The selection of the test strain
In this study, 210 E.coli strains isolated from pigs with
common colibacillosis were used to determine the
MIC90 value. The MIC values were determined by an
agar dilution method as a preliminary screening, accord-
ing to Clinical and Laboratory Standards Institute (CLSI)
reference methods [15]. Strains whose MIC values equal
to the MIC90 value of 210 strains were selected for
pathogenicity test.
Pathogenicity test (the license number: SCXK 2011–
0015) was carried out with 30 Kunming mice (SPF
grade, specific pathogen free grade) purchased from
animal experimental center of southern medical uni-
versity. Every three mice were infected by intraperi-
toneal injection of 0.2 mL E.coli saline suspension
(1 × 109 colony-forming unit, CFU/mL). The blank
control group was given the same amount of saline.
The mice were observed every 3 h after the injection
until 72 h. If there were two or three mice dead in a
group, then the inoculant given to this group was
considered to be of high pathogenicity. The dead
mice were dissected, and gram staining, microscopy
and biochemical identification were carried out for
the bacteria isolated from liver to determine whether
the acquisition was the same as the inoculant.
The bacteria strain that was considered to be of high
pathogenicity was selected out. In the present study, the
bacterium was inoculated into the tissue-cage. Since
cefquinome acts on the bacterium in the tissue-cage
fluid, we need to measure the MIC of cefquinome
against the selected strain in the tissue-cage fluid. Due
to the tissue-cage fluid was limited, we determined the
MIC once again by a micro dilution assay, and the
matrix was the tissue-cage fluid.
The target strain was sent to Guangzhou King med
Center for Clinical Laboratory Co., Ltd. for further
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bacterial identification, and the detection method was
GB/T4789.6-2003.
Antimicrobials, chemicals
Cefquinome Sulfate Injection (Cobactan, the Batch
Number A621B01) was purchased from Merck&Co.
INC. Cefquinome standard was purchased from China
Institute of Veterinary Drugs Control, (Beijing, P.R.
China). Pentobarbital sodium was from Jian Yang
Biotechnology Co., Ltd. Procainamide hydrochloride was
purchased from Xin zheng Co., Ltd., Tianjin Pharma-
ceutical Group.
Animals and surgical procedures
Sixteen healthy castrated cross-bred piglets (Duroc ×
Landrace × Yorkshire) were used, weighing 25-30 kg.
They were housed in a ventilated barn individually. Each
animal was fed antibiotic-free food (guangchubao pre-
mix feed for pig, Guangzhou Zhongwang Feed Com-
pany) twice a day and water was available ad libitum.
The tissue cages were prepared from medical grade sili-
cone rubber tubing and modified slightly from similar
cages described by Sidhu [16]. The length of the tissue
cage was 65 mm, the internal and external diameter
were 13 mm and 18 mm, respectively. Each cage had 24
identical holes and the surface area of each hole was
9.6 mm2, therefore the total exchange surface was
2.3 cm2. Two sterile tissue cages were implanted sub-
cutaneously in each animal, one on each side of the neck
approximately equidistant from the jugular vein and
spinal cord. Surgical insertion was carried out under
deep general anesthesia induced with pentobarbital so-
dium and local infiltration anesthesia by the injection of
procainamide hydrochloride. Animals were allowed to
recover from surgery for 3–4 weeks to permit wound
healing and the growth of granulation tissue into and
around the cages. After the surgery, piglets were treated
with intramuscular penicillin twice a day for 3 days to
prevent infection. The compound aminopyrine injection
was administrated for post-operative analgesia simultan-
eously. About 3–4 weeks after implantation, the surface
of the cage becomes encapsulated by connective tissue,
and the interior is filled with tissue-cage fluid. All proce-
dures involving animals were conducted under the close
supervision and guidance of an experienced veterinary
surgeon. The experimental protocol was approved by
the Committee on the Ethics of animals of South China
Agricultural University (Approval number 2014–04; 10
February 2014).
Animal infection and treatment
Before the infection experiment, 0.5 mL tissue-cage fluid
was sampled from the tissue cage to confirm the tissue-
cage fluid was sterile. The animal with bacterial present
in the tissue-cage fluid before inoculation of E.coli was
excluded from the study. In the current study, no piglets
were excluded from this study due to a prior infection
within the tissue cage. The tissue cages were inoculated
with 1 mL of E.coli saline suspension (1.4 × 108 CFU/mL).
The piglets remained infected without treatment for
two days.
Animals were divided randomly into 8 groups (2 piglets,
4 tissue cages/group). Cefquinome sulfate injection was
administrated intramuscularly at different dosage for dif-
ferent group after bacterial infection. Seven doses (0.2, 0.4,
0.6, 0.8, 1, 2, 4 mg/kg) of cefquinome were given (twice a
day for 3 days) to create a range of different drug expo-
sures. The control group received sterile physiological
saline (1 mL) simultaneously in the same way.
Bacteriological examination of tissue-cage fluid
A 0.5 mL sample of tissue-cage fluid was removed from
the tissue cage prior to every drug administration during
the whole treatment and 12 h, 24 h and 36 h after the last
treatment. Within 1 h after sampling, 100 μL of the
tissue-cage fluid was serially 10-fold diluted in sterile
physiological saline. From each dilution, 0.1 mL was
plated onto MacConkey Agar Plate for overnight incuba-
tion at 37 °C for manual colony counts. The theoretical
limit of detection of this procedure was 20 CFU/mL. The
efficacy of cefquinome was calculated as the decrease in
the amount of the bacteria over 3 days of treatment com-
pared with the bacteria levels before the treatment.
The emergence of resistance under the dosing regimens
in this study was assessed by measuring the MIC for E.coli
recovered from tissue-cage fluid over the 3-day treatment
period and 24 h posttreatment observation period. The
MIC of cefquinome for the test strain was determined in
duplicate using the micro dilution technique established
by the CLSI [15].
Pharmacokinetic sampling and drug analysis
The tissue-cage fluid sample (0.5 mL) was collected from
the inserted tissue cages with a syringe at 1, 3, 6, 9 and
12 h after each dosing. Samples were clarified by centri-
fugation at 3000 g for 10 min and stored at −20 °C until
analyzed.
Cefquinome concentrations in tissue-cage fluid were
analyzed by an Agilent 1200 series high performance
liquid chromatography and an Agilent 6400 triple
quadrupole mass spectrometer equipped with an elec-
trospray ionization source (high performance liquid
chromatography tandem mass spectrometry, HPLC-
MS/MS, Agilent Technologies, and USA). The chro-
matographic separation was achieved on a Phenonenex
BDS C18 column (150 mm × 2 mm; internal diameter,
5 μm, Phenomenex Technologies) at 40 °C with a
thermostat column oven (Agilent 1200 series, Agilent
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Technologies). The mobile phase consisted of solution
A (water with 0.1 % formic acid, V/V) and solution B
(acetonitrile) at 0.25 mL/min flow rate. The gradient
elution was: 0–1 min, 5 % B; 1–5.5 min, 60 % B; 5.5-
10 min, 5 % B. The injection volume was 5 μL. All
tissue-cage fluid samples were allowed to thaw at room
temperature prior to analysis and then aliquots 200 μL
tissue-cage fluid were added to a 1.5 mL micro centri-
fuge tube. Protein precipitation was accomplished by
adding the same volume acetonitrile to the samples.
After vorexing for 30s, and centrifuging at 3000 g for
10 min. 200 μL clear supernatant were pipetted into a
fresh vial and 800 μL of water were added. After
vortex-mixing for 15 s, the samples were filtered
through a 0.22 μm nylon syringe filter (JinTeng Ex-
periment Equipment Company) and then injected into
an auto sampler vial. Cefquinome quantification in the
tissue-cage fluid was linear within a range of 25–
5000 ng/mL and the correlation coefficieent was >0.99.
The lower limit of quantitation was 5 ng/mL. The re-
coveries of cefquinome in tissue-cage fluid were 90.2 ±
3.17 % (mean ± standard deviation, n = 5). The coeffi-
cients of variability (CV %) were all < 8 % for both
intra-assay and inter-assay variation.
Pharmacokinetics/pharmacodynamics (PK/PD) integration
and modeling
The PK/PD parameters, i.e., %T >MIC, AUC0–12/MIC
(AUC, area under the curve) and Cmax/MIC (Cmax, the
maximum concentration) were calculated for each tissue
cage, from 0 to 12 h after every drug administration. This
is due to the dosage regimens. In this study, we treated the
animals with continuous multiple dosing (twice a day for
3 days), with the dosing interval of 12 h. %T >MIC (the
percentage of time that drug concentration remains above
the MIC) and Cmax (the maximum concentration mea-
sured in the tissue-cage fluid) were taken directly from the
concentration-time profiles. AUC0–12, the area under the
concentration-time curve, was calculated by the trapez-
oidal rule. The dose–response effect of the drug was ana-
lyzed by fitting the %T >MIC, AUC0–12/MIC and Cmax/
MIC ratio versus the reduction of bacteria count with a in-
hibitory form of the sigmoid Emax model, through which
we can further elucidate the PK/PD indices required for
various degrees of antibacterial efficacy. The equation used
to characterize the PK/PD parameters and log10CFU/mL
could be described as the following:




Where E is the antibacterial effect, defined as the
change of bacterial count (log10 CFU/mL) after every
drug administration (during 12 h treatment period);
Emax is the change of bacterial count in control sample
(absence of cefquinome) after 12 h incubation; E0 is the
maximum antibacterial effect, determined as the max-
imum change of bacterial count every 12 h; Ce is the
PK/PD parameter being examined (e.g., %T >MIC,
AUC0–12/MIC, or Cmax/MIC); EC50 is the value of PK/
PD index of drug producing 50 % of the maximum anti-
bacterial effect, and N is the Hill coefficient that de-
scribes the steepness of the effect curve. These PD
indices were calculated by running the WinNonlin
(Pharsight Corporation, Mountain View, CA, USA) sig-
moid Emax model to fit the experimental data collected.
Nonlinear regression analysis was used to determine
which PK/PD index best correlated with the bacterial
reduction. Spearman’s rank correlation coefficient was
calculated to evaluate the relationship between drug
efficacy and the PK/PD indices.
Results
MICs of cefquinome for 210 clinical E.coli strains
The MICs of cefquinome for 210 clinical E.coli strains
were shown in Table 1. From the above results, it can be
determined that the MIC90 value was 0.25 μg/mL. So
there were nine strains of bacteria meeting the require-
ments. In the pathogenicity test, bacteria derived from
the dead mice were confirmed to be the same as the
inoculant. One strain with highly pathogenicity was
selected from nine inoculations. The MIC value of the
strain in tissue-cage fluid was further measured to be
0.128 μg/mL. The Serotype of the strain was identified
by Guangzhou King med Center for Clinical Laboratory
Co., Ltd. The bacteriology type was EIEC (Enter invasive
Escherichia Coli) and the serotype was O29 (report
number was HT14020480-1).
The pharmacokinetics of cefquinome
The mean values of AUC0–12 and Cmax of cefquinome in
the tissue-cage fluid following multiple dosing at 0.2, 0.4,
0.6, 0.8, 1, 2 and 4 mg/kg of body weight are shown in
Table 2. The time course of cefquinome concentrations
Table 1 The MICs of cefquinome for 210 clinical E.coli strains









The MIC values were determined by an agar dilution method. From the above
results, it can be determined that the MIC90 value was 0.25 μg/ml
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in the tissue-cage fluid was analyzed using the non-
compartmental method. The AUC0–12 and Cmax in the
tissue-cage fluid increased in a nonlinear fashion with
dose escalation. The AUCs from 0 to 12 h after every
administration, as determined by trapezoidal rule,
ranged from 1.346 ± 0.046 to 20.73 ± 0.064 μg · h/L. The
peak concentrations were directly observed from the
concentration-time curve, ranging from 0.135 ± 0.004 to
2.069 ± 0.070 μg/mL.
PK and PD parameter determination
The efficacy of cefquinome was assessed by determining
the number of viable bacteria in the tissue-cage fluid over
3-day dosing period. The antibacterial time-kill curves are
shown in Fig. 1. Cefquinome administrated at 0.2, 0.4, 0.6,
0.8, 1, 2 and 4 mg/kg reduced the bacterial count (log10
CFU/mL) in tissue-cage fluid by −1.00 ± 0.32, −1.83 ±
0.08, −2.33 ± 0.04, −2.96 ± 0.16, −2.99 ± 0.16, −2.93 ± 0.11,
−3.43 ± 0.18, respectively. In detail, the reduction of bac-
terial count after every drug administration (at 12 h inter-
vals) is shown in Table 3. The bacterial density in the
tissue-cage fluid of untreated controls approximately
remained at 107 CFU/ml during the whole course of treat-
ment. Besides, for the E.coli recovered from the tissue-
cage fluid over the 3-day treatment and 24 h posttreat-
ment observation period, the MIC value did not change,
that is to say, the bacterial strain remained susceptible to
cefquinome throughout the study period.
The relationships between antibacterial effect and PK/
PD parameters (%T >MIC, AUC0–12/MIC, and Cmax/
MIC) are shown in Fig. 2. The %T >MIC was the param-
eter that most strongly correlated with efficacy (R2 = 0.90),
whereas the relationship between efficacy and other pa-
rameters was not nearly as strong (for AUC0–12/MIC, R
2
= 0.62; for Cmax/MIC, R
2 = 0.61). In this study with a
clinical E.coli strain, even the highest dose levels did not
achieve a virtual eradication effect (4-log drop of bacterial
count) over 3-day treatment period. The above studies
indicated that treatment efficacy depended on the percent-
age of time that drug concentration remained above the
MIC.
Magnitudes of the PK/PD parameter required for efficacy
The relationships between antibacterial efficacy and
%T >MIC were assessed by using the inhibitory sigmoid
Table 2 The pharmacokinetics parameters of cefquinome
following multiple-dose in the E.coli-infected piglets
Cefquinome dose AUC0–12 Cmax
(mg/kg of body weight) (μg · h/mL) (μg/mL)
0.2 1.346 ± 0.046 0.135 ± 0.004
0.4 1.553 ± 0.066 0.170 ± 0.007
0.6 2.802 ± 0.044 0.286 ± 0.001
0.8 3.693 ± 0.088 0.396 ± 0.008
1 4.230 ± 0.013 0.448 ± 0.003
2 11.157 ± 0.048 1.175 ± 0.024
4 20.730 ± 0.0640 2.069 ± 0.070
The AUC0–12 and Cmax were the mean values of multiple-dose (six times).
AUC0–12, area under the concentration-time curve from 0 to 12 h after every
administration, was determined by use of the trapezoidal rule; the Cmax was
directly from the concentration-time curve of every administration. The values
shown are means ± standard deviations
Fig. 1 The antibacterial time-kill curve of cefquinome in the tissue-cage model. Two days after infection, seven doses (0.2, 0.4, 0.6, 0.8, 1, 2,
4 mg/kg) of cefquinome were given twice a day for 3 days (indicated by the arrow). The bacterial count in the tissue-cage fluid was monitored
every 12 h, prior to every drug administration during the whole treatment and 12 h, 24 h and 36 h after the last treatment. The values are
means ± standard deviations (two piglets, four tissue-cages)
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Emax model, and the obtained parameters of E0, Emax,
the Hill coefficient and %T >MIC values required for
various degrees of antibacterial efficacy are presented in
Table 4. The estimated %T >MIC values for continuous
1/6-log drop, 1/3-log drop and 1/2-log drop of bacterial
count were 3.97 %, 17.08 % and 52.68 % during 12 h
treatment period of cefquinome, respectively.
Discussion
Antimicrobial PK/PD analyses to identify the PD activity
of antimicrobial agents through the integration of the
PK properties, in vitro potency (MIC), and outcome is
one approach that has proven helpful to the design of
effective dosing regimens in humans and animals [4, 17].
Many reports concerning PK/PD studies of antimicro-
bials against various species of bacteria have been re-
ported, including voriconazole against Candida albicans
[18], biapenem against Psudomonas aeruginosa [19], cef-
taroline fosamil against Methicillin-Resistant Staphylo-
coccus aureus [20], RWJ-54428 against Staphylococcus
aureus, Streptococcus pneumoniae, and Enterococcus fae-
calis [21], and piperacillin against E.coli [22], cefquinome
against Staphylococcus aureus [23].
It has been reported that bacteria have different growth
behavior in vitro and in vivo, this event being particularly
associated to the medium conditions and the source of
substrates. In an in vitro environment, bacteria differ from
those cultivated in vivo in the area of amino acid compos-
ition, synthesis of toxic metabolites and metabolic rate
[22]. The bacteria can adhere to cells and fibers present in
the matrix, making the access of the drug more difficult in
the in vivo infection model. But in vivo infection model
really reflects the interaction between the body, drug and
pathogens. Hence, in the current study, we describe the
PK/PD profile of cefquinome against a clinical E.coli strain
in a more realistic scenario by using an in vivo experimen-
tal infection model.
In the preliminary study, we treated the infected animals
with a single dose of 0.5, 1 and 2 mg/kg b.w. However, the
Table 3 The reduction of bacteria count for each every drug
administration at seven dosages
Times of drug
administration
Doses (mg/kg of body weight)
0.2 0.4 0.6 0.8 1 2 4
1st −0.08 −0.08 −0.10 −0.26 −0.62 −0.56 −0.36
2nd −0.08 −0.07 −0.38 −0.62 −0.26 −0.48 −0.71
3rd −0.10 −0.16 −0.57 −0.61 −0.39 −0.36 −0.38
4th −0.12 −0.43 −0.40 −0.26 −0.72 −0.45 −0.53
5th −0.12 −0.48 −0.43 −0.57 −0.48 −0.57 −0.82
6th −0.50 −0.61 −0.45 −0.61 −0.52 −0.51 −0.63
Total −1.00 −1.83 −2.33 −2.96 −2.99 −2.93 −3.43
The reduction of bacterial count after every drug administration (at 12 h
dosing intervals) is expressed in negative value. And the last line is the total
reduction of bacterial count after six times of drug administration
Fig. 2 Relationships between %T >MIC, AUC0–12/MIC, Cmax/MIC and E. E is defined as the reduction of bacterial count after every drug
administration, at 12 h dosing intervals. The lines represent the best model fits of the data. R2 is the correlation coefficient
Table 4 The values of PK/PD parameter and %T > MIC required
to achieve various degrees of antibacterial efficacy
Parameters Values
Emax (△log CFU/mL) 0.09
E0 (△log CFU/mL) −0.54
Emax - E0 (△log CFU/mL) 0.63
%T >MIC for 1/6-log drop (%) 3.97
%T >MIC for 1/3-log drop (%) 17.08
%T >MIC for 1/2-log drop (%) 52.68
Slope (N) 1.73
Emax, the difference of the bacterial count in the control sample (absence of
cefquinome); E0, the maximum antibacterial effect during 12 h treatment
period; N, the Hill coefficient that describes the steepness of the effect curve.
%T >MIC, the values of cefquinome required to achieve 1/6-log drop, 1/3-log
drop and 1/2-log drop against the clinical E.coli strain during 12 h
treatment period
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results were unsatisfactory. After the drug administration,
the bacteria counts in the tissue-cage fluid have certain re-
duction (all less than 1-log for 0.5, 1 and 2 mg/kg) in the
first 12 h. But the bacteria count increased again during
12-24 h. The duration of time that the drug inhibited the
growth of the bacteria was short. By monitoring the drug
concentration, we discovered that with the course of drug
elimination, the drug concentration exceeded the MIC
momently and then fell below the MIC. Then we treated
the infected animals with multiple dosing and reduced the
dosing interval to make the T >MIC longer. The experi-
ment results indicated that the values of %T >MIC rose
gradually with increasing dosage, varying from 0 % to
100 %.
The previous studies about in vivo PK/PD of the anti-
bacterial agent were mostly against various standard
strains, hardly any against a clinical bacterial strain. In
this study, we measured the MIC90 of cefquinome for
210 E.coli strains isolated from pigs, and investigated the
response of a clinical E.coli strain (the MIC value for this
bacteria strain equals to the MIC90 value) to repeated
cefquinome exposure in an in vivo experimental infec-
tion model. This is critical for optimal dosage regimens
to treat the diseases caused by E.coli.
The results of the current multiple-dosing regimen
studies confirmed that %T >MIC has a favorable correl-
ation with the efficacy of cefquinome. The results obtained
in the present study were consistent with the results of
other β-lactams in the previous studies. For instance,
Andes [24] reported that the in vitro bactericidal effect
was time-dependent and that %T >MIC was an important
PK/PD parameter for β-lactams with a weak PAE. There
were also studies [25] reporting that cephalosporins act as
time-dependent antimicrobials, and the most appropriate
PK/PD parameter to describe drug efficacy was the time
that the drug concentration exceeds the MIC. As to
cefquinome, it has been reported that %T >MIC was the
PK/PD index that best described the efficacy of the anti-
bacterial agent in a neutropenic mouse thigh model of
Staphylococcus aureus infection [23].
Many in vitro and in vivo PK/PD models have sug-
gested that the magnitude of the %T >MIC is predict-
ive index of cephalosporin efficacy. In those reports,
%T >MIC ranges from 25 % to 70 % for defined thera-
peutic endpoint [26–28]. The previous studies about
Ceftaroline fosamil (PPI-0903 or TAK-599) against
E.coli 25922 [20] showed that the bacteriostatic effect,
a 1-log drop and a 2-log drop were achieved when the
%T >MIC reached 32 %, 44 % and 50 %, respectively.
With respect to RWJ-54428 against Enterococcus fae-
calis in the murine neutropenic thigh infection model,
it was reported [21] that the ranges of %T >MIC for
bacteriostatic and maximal effect (the maximal reduc-
tion in bacterial count was 1.7) were 30 % to 46 % and
55 % to 60 %, respectively. The study of cefquinome in
a neutropenic mouse thigh model of Staphylococcus
aureus infection indicated that the %T >MICs ranged
from 30.28 to 36.84 % for bacteriostatic effect, 34.38 to
46.70 % for a 0.5-log drop, and 43.50 to 54.01 % for a
1-log drop [23].
In the current study, an analysis of the results showed
that during 12 h treatment period, continuous bacterial
count reduction by 1/6-log, 1/3-log and 1/2-log drop
were achieved when the %T >MIC reached 3.97 %,
17.08 % and 52.68 %, respectively. These values are not
identical to the activities of other cephalosporin. This
may be due to different time span (12 h in this study
versus 24 h in other studies), or diversity of animal
models, different bacteria species or inoculation level in
these studies.
Conclusions
The current study characterized the in vivo response
of a clinical E.coli strain to cefquinome in a piglet
tissue-cage infection model after different dosing. The
data derived from this study showed that cefquinome
exhibit time-dependent killing against E.coli in an in
vivo model, and the most important PK/PD parameter
was %T >MIC. From the results of the present study,
it can be assumed that when %T >MIC reached
52.68 %, cefquinome could be expected to be effective
against bacterial strains for which the MIC value is
below the MIC90 of 0.128 μg/ml (3-log drop of bacter-
ial count can be achieved after six times of drug ad-
ministration, twice a day, 3 days). Since the current
study investigated the in vivo PK and PD of cefqui-
nome against a clinical E.coli strain which represents
the MIC90 for 210 clinical strains, thus the results are
meaningful for designing reasonable clinical treatment
regimens.
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